GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4

GW Pharmaceuticals (NASDAQ:GWPH) has released what is very possibly its final earnings report as an independent company.

On Tuesday, the maker of drugs derived from cannabis published its fourth-quarter results, which revealed that it earned $148 million in revenue for the period. That was nearly 36% higher on a year-over-year basis. But its net loss deepened across that stretch of time, to just over $29 million ($0.08 per share) from the fourth-quarter 2019 deficit of nearly $25 million.